Background: Nilotinib is a tyrosine kinase inhibitor with high target specificity. Here, we characterized the effects of nilotinib for the first time on CD4
Introduction
Nilotinib (AMN107, Tasigna; Novartis Pharma, Basel, Switzerland) is a new, orally active, selective inhibitor of the ABL/BCR-ABL, CSF-1R, DDR, KIT, and PDGFR tyrosine kinases, that is more potent against chronic myeloid leukemia (CML) cells in vitro than is imatinib. Like imatinib, nilotinib acts through competitive inhibition at the ATP-binding site of BCR-ABL, leading to the inhibition of tyrosine phosphorylation of proteins that are involved in the intracellular signal transduction mediated BCR-ABL. Nilotinib has a higher binding affinity and selectivity for the ABL kinase than does imatinib, which translates into 20-to 50-fold greater inhibitory activity than imatinib in imatinib-sensitive CML cells and 3-to 7-times the activity in imatinibresistant cell lines with mutant ABL kinases [1] [2] [3] [4] [5] .
Results from a phase I dose escalation study performed in patients with imatinib-resistant CML and Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL) indicated that nilotinib produced significant hematologic and cytogenetic responses in all phases of CML [2] . Furthermore, 400 mg nilotinib was administered orally twice daily, proved to be very active and safe in phase II study of patients with chronic phase CML and accelerated-phase CML post-imatinib resistance and intolerance [6, 7] . Now, clinical trials with nilotinib are ongoing in patients with imatinib-resistant or imatinib-intolerant accelerated-phase CML and Phpositive ALL [7, 8] .
Naturally arising CD4 + CD25 + regulatory T cells (Tregs) have the potential to suppress aberrant immune responses and to regulate peripheral T-cell homeostasis [9] . Tregs play a crucial role in both the induction and maintenance of tolerance. This active immune regulation may contribute not only to the control of immune responses to self-antigens, thereby preventing autoimmune diseases, but also the control of responses to non-self molecules in adaptive immunity. Numerous experimental and clinical studies indicate that manipulating the balance between regulatory and effector T cells is an effective strategy to control immune responsiveness after transplantation. Therefore a better understanding of regulatory T cells biology is essential for exploiting this strategy to clinical therapy [10] .
There is evidence that imatinib and dasatinib have inhibitory effects on immune reconstitution and T cell proliferation and function [11] [12] [13] [14] [15] . Furthermore, nilotinib was shown to have an inhibitory effect on CD8 + T cells in vitro [16] , however little is known about its effects on Tregs [17] . Therefore, we wondered to what extent and by which mechanisms nilotinib affects the immune system, particularly for Tregs. In this study, we examined the effects of nilotinib on both Tregs and CD4 + CD25 -T cells. We indicate that nilotinib similarly inhibits proliferation and function of Tregs as well as CD4 + CD25 -T cells only at high concentrations greater than 10 μM nilotinib which exceeds the therapeutic range achieved with current standard dosing schedules.
Design and Methods

Nilotinib, imatinib and dasatinib
Nilotinib and imatinib were provided by Novartis Pharmaceuticals, Basel, Switzerland. Dasatinib was purchased from Bristol-Myers Squibb, New York, NY, USA and stored in aliquots at -20°C as 10 mM stock solution in DMSO.
Cell isolation and culture
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Biocoll Separation Solution (Biochrom, Berlin, Germany) as described previously [18] . CD4 + CD25
+ T cells and CD4 + CD25 -T cells were selected from the total PBMCs using CD4 + CD25 + regulatory T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer's instruction. This procedure led to the complete positive selection of CD4 + CD25 + T cells (purity ≥ 90%), and negative depletion of CD4 + CD25 -T cells, as measured by flow cytometry (FACSan, Becton Dickinson, Franklin Lake, NJ, USA). Cells were cultured in RPMI 1640 (Biochrom AG, Berlin, Germany) supplemented with 10% human AB serum (Germany Red Cross Blood Center, Ulm, Germany), 2 mM L-glutamine and 100 units/ml penicillin-streptomycin (Invitrogen Gibco, Grand Island, USA). 
CFSE-based cell proliferation
Cytokine analysis
CD4
+ CD25 + T cells and CD4 + CD25 -T cells were stimulated with anti-CD3, anti-CD28 and IL-2 in the presence or absence of 25 μM nilotinib. After 4 days incubation, supernatants were collected and analyzed for cytokines according to the instruction of Proteome Profiler Array (R&D Systems, Minneapolis, MN, USA).
Flow cytometry
Cells were phenotyped by 4-or 5-color Abs and measured by flow cytometry as described previously [18] . The following conjugated Abs were used: CD4* fluorescein isothiocyanate (FITC), CD4*phycoerythrinCyanine 7 (PE-Cy7), CD25* phycoerythrin-Cyanine 5 (PE-Cy5), CD25* Allophycocyanin (APC) (BD Pharmingen™, Heidelberg, Germany), transcription factor forkhead box P3 (FoxP3)*phycoerythrin (PE) (PCH 101; eBioscience, San Diego, CA), and glucocorticoid-induced tumor necrosis factor receptor (GITR)*PE (R&D Systems, Minneapolis, MN, USA),
Western blotting
CD4
+ CD25 + T cells, CD4 + CD25 -T cells or Jurkat T cells (1 × 10 6 cells/well) were treated with different concentrations of imatinib, nilotinib or dasatinib for 1 hour and stimulated with anti-CD3/CD28 for 15 minutes. Western blotting analysis was performed as previously described [18] by using the following antibodies: phospho-Lck, Lck, phospho-ZAP-70, ZAP-70, phospho-p44/ 42 MAP kinase, p44/42 MAP kinase, phospho-Akt, Akt, src, phospho-src family (Tyr416), non-phospho-src (Tyr416), phospho-src (Tyr527), non-phospho-src (Tyr527), phospho-NF-B p65 (Ser536)(93H1) and NF-B p65 from Cell Signaling Technology, USA and antiActin C-11 (Santa Cruz Biotechnology, Heidelberg, Germany) to confirm equal protein loading.
Statistical analysis
Statistical analysis was performed with SPSS software. Data were presented as mean ± standard deviation (SD). Statistical significance of differences between groups was evaluated using one-way-ANOVA (post hoc Scheffe test). The value of P < .05 was considered to be statistically significant.
Results
In phase I clinical studies, at the steady-state, mean serum levels of nilotinib were: 1.0 μM at 400 mg once daily, 1.7 μM at 400 mg twice daily, and 2.3 μM at 600 mg twice daily; at 400 mg twice daily, the dose selected for phase II studies, steady state mean serum peak levels of drug were 3.6 μM [2] . Based upon this, to include the clinically relevant dose range of nilotinib, all assays described in this manuscript were performed at concentrations between 1 and 25 μM. and in situations of aberrant immune activity (autoimmunity, GVHD and transplant rejection) cytokines are involved in the pathophysiologic sequelae [22] [23] [24] . CD4 + CD25
+ T cells and CD4 + CD25 -T cells were stimulated and treated with or without 25 μM nilotinib. After 4 days of incubation, supernatants were collected for cytokine analysis (Figure 4 ). Nilotinib inhibited multiple cytokines production including pro-inflammatory cytokines (TNF-α, IFN-γ, and IL-1rα) and chemotactic factors (MIP-1β, MCP-1, RANTES, IP-10, etc) by CD4 + CD25
-T cells at a high concentration of 25 μM. CD4 + CD25 + T cells only secreted few cytokines compared with CD4 + CD25 -T cells ( Figure 4C and 4D ). T-cell receptor (TCR)-mediated activation Tregs were proved to have very low in vitro proliferative capacity and they do not produce cytokines compared with other T cells [25] . However, nilotinib inhibits the cytokines production by CD4 + CD25 + T cells significantly at a concentration of 25 μM.
Nilotinib down-regulates the expression of CD4
+ CD25 + T
cell-specific molecules in a dose-dependent manner
To investigate the inhibitory effect of nilotinib on the phenotype of CD4 + CD25 high T cells, CD4 + CD25 + T cells were stimulated with anti-CD3, anti-CD28 and IL-2 for 4 days. After stimulation, the expression of FoxP3 and GITR were up-regulated compared with unstimulated cells. However, nilotinib only at a concentration of 25 μM could down-regulate the expression of FoxP3 (P = .047) and GITR (P = .004) significantly ( Figure 5 ) which was associated with the data in proliferation assay. Figure 6A .
Furthermore, we compared the effects of nilotinib, imatinib and dasatinib on TCR, Src and NF-B dependent signal cascades in Jurkat T cells. Figure 6B clearly shows that exposure of cells to low nanomolar concentrations of dasatinib attenuated the phosphorylation levels of Lck, ZAP-70, ERK 1/2, AKT, Src Tyr416, Src Tyr527 and NF-B P65 in a dose-dependent manner. Imatinib only showed significant effects at a dose of 25 μM which is 100-fold higher concentrations than dasatinib. In contrast, nilotinib showed no significant inhibition of TCR, Src and NF-B signal events, even at a high concentration of 25 μM.
Discussion
The novel, selective Abl inhibitor nilotinib was designed to interact with the ATP-binding site of BCR-ABL with a higher affinity than imatinib. Besides being significantly more potent when compared with imatinib, nilotinib also maintains activity against most of the BCR-ABL point mutants that confer to imatinib resistance. In phase I/II clinical trials administration of nilotinib resulted in cytogenetic and hematologic responses in imatinib-refractory CML patients [2] . Now nilotinib represents an additional therapeutic option for patients with progressive CML [26] .
Naturally occurring Tregs represent between 5% and 10% of the CD4 + T cell subset in the peripheral blood of healthy volunteers [27, 28] . Studies of T-cell mediated immunoregulation provide crucial insights into the immune system's task of balancing immunologic selftolerance, while preserving tumor and anti-microbial immunity. Tregs have emerged as key cellular components that mediate this process [9] . In the stem cell transplantation setting, Tregs have proved to be effective in suppressing lethal graft versus host disease (GVHD). Importantly, this suppression does not abrogate the beneficial graft versus tumor (GVT) effect in most murine models. Moreover, in preliminary studies, donor Tregs promote engraftment and enhance immune reconstitution [9] . Recently, patients with CML are treated with nilotinib when the therapy with imatinib failed or caused serious side effects [2] . The same applies to the situation of CML patients after allogeneic stem cell transplantation. Moreover, patients with a history of nilotinib administration before transplantation are likely to be treated again by the drug in the case of a relapse of the disease after allogeneic stem cell transplantation. Therefore, the effect of nilotinib on Treg function needs to be monitored [9, 29] . 
In an effort to investigate the potential role as nilotinib as an immunomodulatory agent, we set our studies on three important parts of T cell responses: TCR signaling and expression of activation markers, cytokine production, and proliferation [13] . In our study, we observed that therapeutic doses of nilotinib did not hamper the proliferation and function, of either CD4 + CD25 + T cells or CD4 + CD25 -T cells. Nilotinib only showed significant inhibitory effect on CD4 + CD25 + T cells or CD4 + CD25 -T cells at a concentration higher than 10 μM. However, Chen et al showed that nilotinib inhibits phytohemagglutinin (PHA)-induced proliferation of CD8 + T cells in vitro at therapeutically relevant concentrations (0.5-4 μM) [16] . Similar results were also shown by Blake et al. [30] . We think the difference between us might be the reason we use anti-CD3, anti-CD28 and IL-2 to stimulate CD4 + CD25 + T cells and CD4 + CD25 -T cells which is stronger than PHA that could partly abrogate the inhibitory effect of nilotinib on cells. However, the correlates between nilotinib and T cells in vivo are still unknown and it is still not clear which assays are more appropriate in gauging the suppressive effect of nilotinib. Furthermore, our results present that nilotinib did not affect the suppressive capacity of Tregs at therapeutically relevant concentrations, only at a concentration of 5 μM. Tregs and nilotinib act in synergy to reduce CD4 + CD25 -T cells proliferation when co-cultured at the same time. We propose that the reason is that the direct inhibitory effect of nilotinib on CD4 + CD25 -T cells might be stronger than the indirectly inhibitory effect on the proliferation of CD4 The recent identification of the FoxP3, as a more specific marker of Tregs better defines the regulatory subset of CD4 + T cells from activated effector T cells [9] . Based on consistent findings in mice and humans, FoxP3 is considered the "master regulator" of Tregs [9] . GITR is highly and constitutively expressed on the surface of mouse and human Tregs. Stimulation of GITR in vitro or in vivo or the removal of T cells expressing high levels of GITR leads to autoimmunity in normal mice [31, 32] . In our study, we observed that high doses of nilotinib down-regulated the expression of FoxP3 and GITR in Tregs in a dose-dependent manner, which was accordance to the function of Tregs.
In the next step, we investigated the signaling events in CD4+CD25+ T cells and CD4+CD25-T cells after treatment with nilotinib. Consistent with previous data, nilotinib did not impair the phosphorylation levels of Lck and ZAP70 in cells even at a high concentration of 25 μM. Furthermore, we compared the inhibitory effects of imatinib, nilotinib and dasatinib on signal events against Jurkat T cells. An interesting phenomenon is that imatinib-resistant CML patients who develop resistance against nilotinib may still show a response to dasatinib, and patients with resistance against dasatinib may still respond to nilotinib [33] . Another remarkable aspect is that, in contrast to nilotinib, dasatinib exhibits a number of clinically relevant side effects including cytopenia and pleural effusions when applied at approved doses [34] . All these observations point to major differences of the three tyrosine kinase inhibitors regarding their mechanism of action and target profiles in pathological as well as normal cells [33] . We demonstrated that among the three drugs, dasatinib showed the highest potency on TCR, Src and NF-B signaling events, while nilotinib did not show inhibitory effects on this signaling transduction cascade, which is in accordance with the molecular mechanisms of the three drugs. Previous biochemical studies have already revealed pronounced differences between the three tyrosine kinase inhibitors with regard to their selectivity. Nilotinib, like imatinib, inhibits BCR-ABL, c-ABL, c-KIT, and PDGFR, although with greater potency and selectivity for BCR-ABL [5] . The selectivity of nilotinib against BCR-ABL (relative to other targets, such as Src-family or c-Kit kinases) may account for the high level of efficacy unaccompanied by higher rates of severe myelosuppression [6] . Dasatinib, on the other hand, has been developed as a dual-specificity Abl-and Src-family kinase inhibitor [35] . Moreover, several pathways of the immune system could be severely affected by continuous high doses of dasatinib, harboring significant risks for immunosuppression of patients treated over a long period of time [33] . Recently, our group shows that imatinib inhibits the proliferation and function of Tregs and CD8 + T cells as a concentration range of 1-5 μM, while the range for dasatinib is 5-10 nM [18, 36, 37] . Larmonier et al reported that imatinib inhibits the suppressive function and FoxP3 expression on Tregs as low as 1 μM. In vivo study indicated that imaitnib decreases Treg frequency and impairs their immunosuppressive function for mice treated with imatinib but imatinib does not impair the production of IL-10 and TGF-β in vitro [38] . Dasatinib proves to be much more potent than imatinib and nilotinib on Tregs and CD8 + T cells. Chow et al. reported that although nilotinib exhibits only a minor apoptosis-inducing effect in the T-cell lines, it exerts a considerable, dose-dependent cytotoxicity in the B-cell lines. The activity of nilotinib is not restricted to Bcr-Abl, c-kit, or PDGFR-positive cells, but also extends to lymphatic cell lines of B-cell origin at a concentration of 5 μM [39] . Furthermore, Hipp et al. indicated that the multitargeted tyrosine serine/threonine kinase inhibitor sunitinib could significantly decrease the number of Tregs in the peripheral blood of mice treated with subtoxic doses of the drug, but does not show an impaired CD8 + T cell response [40] . As all these compounds have already entered clinical practice, it would be useful to further define the appropriate clinical angle, because it would allow a rational approach to balance effector T cells and Tregs especially for patients after allogeneic stem cell transplantation.
In conclusion, our results show that the tyrosine kinase inhibitor nilotinib can inhibit both proliferation and function of Tregs and CD4 + CD25 -T cells only at high concentrations, which exceeds therapeutically relevant concentrations of the drug. Since nilotinib has less inhibitory effects on Tregs than imatinib and dasatinib, nilotinib might constitute a good choice for patients in transplantation settings.
